Grifols Therapeutics Inc.

Talecris Biotherapeutics, Inc.

Jeffrey A Yuziuk

James Rebbeor

Jonathan S Strauss

Valery Novokhatny

Christopher J Stenland

Marina N Korneyeva

Scott A Cook

Rita T Bradley

Jarrett C Terry

Christopher A Dadd

Jonathan D Kent

Disclosed is both a method for preparing a plasminogen and a method for preparing a reversibly inactive acidified plasmin by activating the plasminogen. The prepared plasminogen is typically purified from a fraction obtained in the separation of immunoglobulin from Fraction II+III chromatographic process and eluted at a low pH. The prepared plasmin is isolated and stored with a low pH-buffering capacity agent to provide a substantially stable formulation. The reversibly inactive acidified plasmin may be used in the administration of a thrombolytic therapy.

Composition and method for preparing plasminogen

Disclosed is both a process for producing a reversibly inactive acidified plasmin by activating plasminogen and a process for producing a purified plasminogen. The produced plasmin is isolated and stored with a low pH-buffering capacity agent to provide a substantially stable formulation. The purified plasminogen is typically purified from a fraction obtained in the separation of immunoglobulin from Fraction II+III chromatographic process and eluted at a low pH. The reversibly inactive acidified plasmin may be used in the administration of a thrombolytic therapy.

Process for the production of a reversibly inactive acidified plasmin composition

Growing community of inventors

Garner, NC, United States of America

Jeffrey A Yuziuk